Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

The cost of the procurement has surged to C$27.7 billion (roughly $20.2 billion USD), nearly 50% higher than estimates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Supporting his view, Truist Securities analyst Bill Chappell maintained e.l.f. Beauty with a Buy and raised the price target from $125 to $130, while Baird analyst Joel Beatty maintained the stock ...

Bank of America Corp. Dep. Pfd. (Rep. 1/1000th 5.875% Non-Cum. Perp. Pfd. Series HH)-0.51% Bank of America Corp. Dep. Pfd. (Rep. 1/1000th Interest in a share of Pfd. Series E) 0.05% Bank of ...